BioCentury
ARTICLE | Clinical News

Tirasemtiv: Phase IIb started

November 5, 2012 8:00 AM UTC

Cytokinetics began the international Phase IIb BENEFIT-ALS trial of oral tirasemtiv in about 400 ALS patients. Patients will receive twice-daily 125 mg tirasemtiv in a 1-week, open-label period follow...